EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling

Ankang Lu, Caojian Zuo, Yuhu He, Guilin Chen, Lingjuan Piao, Jian Zhang, Bing Xiao, Yujun Shen, Juan Tang, Deping Kong, Sara Alberti, Di Chen, Shenkai Zuo, Qianqian Zhang, Shuai Yan, Xiaochun Fei, Fei Yuan, Bin Zhou, Shengzhong Duan, Yu Yu & 5 others Michael Lazarus, Yunchao Su, Richard M. Breyer, Colin D. Funk, Ying Yu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD). Prostacyclin analogs are widely used in the management of PAH patients; however, clinical efficacy and long-term tolerability of some prostacyclin analogs may be compromised by concomitant activation of the E-prostanoid 3 (EP3) receptor. Here, we found that EP3 expression is upregulated in pulmonary arterial smooth muscle cells (PASMCs) and human distal pulmonary arteries (PAs) in response to hypoxia. Either pharmacological inhibition of EP3 or Ep3 deletion attenuated both hypoxia and monocrotaline-induced pulmonary hypertension and restrained extracellular matrix accumulation in PAs in rodent models. In a murine PAH model, Ep3 deletion in SMCs, but not endothelial cells, retarded PA medial thickness. Knockdown of EP3α and EP3β, but not EP3γ, isoforms diminished hypoxia-induced TGF-β1 activation. Expression of either EP3α or EP3β in EP3-deficient PASMCs restored TGF-β1 activation in response to hypoxia. EP3α/β activation in PASMCs increased RhoA-dependent membrane type 1 extracellular matrix metalloproteinase (MMP) translocation to the cell surface, subsequently activating pro'MMP-2 and promoting TGF-β1 signaling. Activation or disruption of EP3 did not influence PASMC proliferation. Together, our results indicate that EP3 activation facilitates hypoxia-induced vascular remodeling and pulmonary hypertension in mice and suggest EP3 inhibition as a potential therapeutic strategy for pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)1228-1242
Number of pages15
JournalJournal of Clinical Investigation
Volume125
Issue number3
DOIs
StatePublished - Mar 2 2015

Fingerprint

Pulmonary Hypertension
Prostaglandins
Smooth Muscle Myocytes
Pulmonary Artery
Lung
Epoprostenol
Extracellular Matrix
Monocrotaline
Matrix Metalloproteinase 14
Matrix Metalloproteinase 2
Chronic Obstructive Pulmonary Disease
Hypoxia
Rodentia
Protein Isoforms
Endothelial Cells
Cell Proliferation
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. / Lu, Ankang; Zuo, Caojian; He, Yuhu; Chen, Guilin; Piao, Lingjuan; Zhang, Jian; Xiao, Bing; Shen, Yujun; Tang, Juan; Kong, Deping; Alberti, Sara; Chen, Di; Zuo, Shenkai; Zhang, Qianqian; Yan, Shuai; Fei, Xiaochun; Yuan, Fei; Zhou, Bin; Duan, Shengzhong; Yu, Yu; Lazarus, Michael; Su, Yunchao; Breyer, Richard M.; Funk, Colin D.; Yu, Ying.

In: Journal of Clinical Investigation, Vol. 125, No. 3, 02.03.2015, p. 1228-1242.

Research output: Contribution to journalArticle

Lu, A, Zuo, C, He, Y, Chen, G, Piao, L, Zhang, J, Xiao, B, Shen, Y, Tang, J, Kong, D, Alberti, S, Chen, D, Zuo, S, Zhang, Q, Yan, S, Fei, X, Yuan, F, Zhou, B, Duan, S, Yu, Y, Lazarus, M, Su, Y, Breyer, RM, Funk, CD & Yu, Y 2015, 'EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling', Journal of Clinical Investigation, vol. 125, no. 3, pp. 1228-1242. https://doi.org/10.1172/JCI77656
Lu, Ankang ; Zuo, Caojian ; He, Yuhu ; Chen, Guilin ; Piao, Lingjuan ; Zhang, Jian ; Xiao, Bing ; Shen, Yujun ; Tang, Juan ; Kong, Deping ; Alberti, Sara ; Chen, Di ; Zuo, Shenkai ; Zhang, Qianqian ; Yan, Shuai ; Fei, Xiaochun ; Yuan, Fei ; Zhou, Bin ; Duan, Shengzhong ; Yu, Yu ; Lazarus, Michael ; Su, Yunchao ; Breyer, Richard M. ; Funk, Colin D. ; Yu, Ying. / EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. In: Journal of Clinical Investigation. 2015 ; Vol. 125, No. 3. pp. 1228-1242.
@article{2b813f2b835c4ea88815a55512c89018,
title = "EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling",
abstract = "Pulmonary arterial hypertension (PAH) is commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD). Prostacyclin analogs are widely used in the management of PAH patients; however, clinical efficacy and long-term tolerability of some prostacyclin analogs may be compromised by concomitant activation of the E-prostanoid 3 (EP3) receptor. Here, we found that EP3 expression is upregulated in pulmonary arterial smooth muscle cells (PASMCs) and human distal pulmonary arteries (PAs) in response to hypoxia. Either pharmacological inhibition of EP3 or Ep3 deletion attenuated both hypoxia and monocrotaline-induced pulmonary hypertension and restrained extracellular matrix accumulation in PAs in rodent models. In a murine PAH model, Ep3 deletion in SMCs, but not endothelial cells, retarded PA medial thickness. Knockdown of EP3α and EP3β, but not EP3γ, isoforms diminished hypoxia-induced TGF-β1 activation. Expression of either EP3α or EP3β in EP3-deficient PASMCs restored TGF-β1 activation in response to hypoxia. EP3α/β activation in PASMCs increased RhoA-dependent membrane type 1 extracellular matrix metalloproteinase (MMP) translocation to the cell surface, subsequently activating pro'MMP-2 and promoting TGF-β1 signaling. Activation or disruption of EP3 did not influence PASMC proliferation. Together, our results indicate that EP3 activation facilitates hypoxia-induced vascular remodeling and pulmonary hypertension in mice and suggest EP3 inhibition as a potential therapeutic strategy for pulmonary hypertension.",
author = "Ankang Lu and Caojian Zuo and Yuhu He and Guilin Chen and Lingjuan Piao and Jian Zhang and Bing Xiao and Yujun Shen and Juan Tang and Deping Kong and Sara Alberti and Di Chen and Shenkai Zuo and Qianqian Zhang and Shuai Yan and Xiaochun Fei and Fei Yuan and Bin Zhou and Shengzhong Duan and Yu Yu and Michael Lazarus and Yunchao Su and Breyer, {Richard M.} and Funk, {Colin D.} and Ying Yu",
year = "2015",
month = "3",
day = "2",
doi = "10.1172/JCI77656",
language = "English (US)",
volume = "125",
pages = "1228--1242",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling

AU - Lu, Ankang

AU - Zuo, Caojian

AU - He, Yuhu

AU - Chen, Guilin

AU - Piao, Lingjuan

AU - Zhang, Jian

AU - Xiao, Bing

AU - Shen, Yujun

AU - Tang, Juan

AU - Kong, Deping

AU - Alberti, Sara

AU - Chen, Di

AU - Zuo, Shenkai

AU - Zhang, Qianqian

AU - Yan, Shuai

AU - Fei, Xiaochun

AU - Yuan, Fei

AU - Zhou, Bin

AU - Duan, Shengzhong

AU - Yu, Yu

AU - Lazarus, Michael

AU - Su, Yunchao

AU - Breyer, Richard M.

AU - Funk, Colin D.

AU - Yu, Ying

PY - 2015/3/2

Y1 - 2015/3/2

N2 - Pulmonary arterial hypertension (PAH) is commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD). Prostacyclin analogs are widely used in the management of PAH patients; however, clinical efficacy and long-term tolerability of some prostacyclin analogs may be compromised by concomitant activation of the E-prostanoid 3 (EP3) receptor. Here, we found that EP3 expression is upregulated in pulmonary arterial smooth muscle cells (PASMCs) and human distal pulmonary arteries (PAs) in response to hypoxia. Either pharmacological inhibition of EP3 or Ep3 deletion attenuated both hypoxia and monocrotaline-induced pulmonary hypertension and restrained extracellular matrix accumulation in PAs in rodent models. In a murine PAH model, Ep3 deletion in SMCs, but not endothelial cells, retarded PA medial thickness. Knockdown of EP3α and EP3β, but not EP3γ, isoforms diminished hypoxia-induced TGF-β1 activation. Expression of either EP3α or EP3β in EP3-deficient PASMCs restored TGF-β1 activation in response to hypoxia. EP3α/β activation in PASMCs increased RhoA-dependent membrane type 1 extracellular matrix metalloproteinase (MMP) translocation to the cell surface, subsequently activating pro'MMP-2 and promoting TGF-β1 signaling. Activation or disruption of EP3 did not influence PASMC proliferation. Together, our results indicate that EP3 activation facilitates hypoxia-induced vascular remodeling and pulmonary hypertension in mice and suggest EP3 inhibition as a potential therapeutic strategy for pulmonary hypertension.

AB - Pulmonary arterial hypertension (PAH) is commonly associated with chronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD). Prostacyclin analogs are widely used in the management of PAH patients; however, clinical efficacy and long-term tolerability of some prostacyclin analogs may be compromised by concomitant activation of the E-prostanoid 3 (EP3) receptor. Here, we found that EP3 expression is upregulated in pulmonary arterial smooth muscle cells (PASMCs) and human distal pulmonary arteries (PAs) in response to hypoxia. Either pharmacological inhibition of EP3 or Ep3 deletion attenuated both hypoxia and monocrotaline-induced pulmonary hypertension and restrained extracellular matrix accumulation in PAs in rodent models. In a murine PAH model, Ep3 deletion in SMCs, but not endothelial cells, retarded PA medial thickness. Knockdown of EP3α and EP3β, but not EP3γ, isoforms diminished hypoxia-induced TGF-β1 activation. Expression of either EP3α or EP3β in EP3-deficient PASMCs restored TGF-β1 activation in response to hypoxia. EP3α/β activation in PASMCs increased RhoA-dependent membrane type 1 extracellular matrix metalloproteinase (MMP) translocation to the cell surface, subsequently activating pro'MMP-2 and promoting TGF-β1 signaling. Activation or disruption of EP3 did not influence PASMC proliferation. Together, our results indicate that EP3 activation facilitates hypoxia-induced vascular remodeling and pulmonary hypertension in mice and suggest EP3 inhibition as a potential therapeutic strategy for pulmonary hypertension.

UR - http://www.scopus.com/inward/record.url?scp=84924028882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924028882&partnerID=8YFLogxK

U2 - 10.1172/JCI77656

DO - 10.1172/JCI77656

M3 - Article

VL - 125

SP - 1228

EP - 1242

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -